Gallbladder Cancer Market Report and Forecast 2025-2034
Description
The gallbladder cancer market size was valued at USD 87.57 Million in 2024, driven by the increasing research and development activities for new treatment among people across the 7 major markets. The market size is anticipated to grow at a CAGR of 5.56% during the forecast period of 2025-2034 to achieve a value of USD 150.44 Million by 2034.
Gallbladder Cancer: Introduction
Gallbladder cancer originates from abnormal cell growth within the gallbladder, a small, pear-shaped organ located beneath the liver on the right side of the abdomen. Responsible for storing bile, a digestive fluid produced by the liver, the gallbladder plays a crucial role in the digestive process. Though uncommon, gallbladder cancer poses a significant challenge due to its tendency to remain asymptomatic in its early stages, often leading to late detection and a poor prognosis. The insidious nature of this cancer is exacerbated by its subtle symptoms or the absence thereof, allowing it to progress unnoticed.
Common signs such as upper right abdominal pain, bloating, unexplained weight loss, and jaundice, characterized by yellowing of the skin and eyes, might indicate the presence of gallbladder cancer, but these indicators often manifest in later stages, complicating timely diagnosis and treatment.
Gallbladder Cancer Market Analysis
The market for gallbladder cancer treatment is witnessing a transformative phase, driven by several key factors. The rise in demand and emphasis on targeted therapy treatments is further anticipated to bolster the gallbladder cancer market growth. For example, Gemcitabine, a combination therapy, has shown promising results, indicating an increased response rate compared to traditional treatments using 5-FU alone. The efficacy of gemcitabine in conjunction with cis-platinum and capecitabine highlights its potential as a viable treatment option.
Pembrolizumab has also shown positive results in tumours with high microsatellite instability/deficient mismatch repair, and entrectinib, a tyrosine kinase inhibitor, has potential use in NTRK gene fusion-positive tumours, providing a new pathway for gallbladder cancer treatment. These developments signify a shift towards more targeted and potentially more effective therapies, exhibiting hopeful market growth.
Gallbladder Cancer Market Segmentations
Gallbladder Cancer Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type Germany
France
Italy
Spain
United Kingdom
The market is experiencing significant growth driven by the rising prevalence of gallbladder cancer, especially among the geriatric population, which underscores the urgency for precision treatments. The statistics projected by the American Cancer Society for 2023 in the United States display concern by mentioning that a substantial number of new cases and related deaths are anticipated to occur in 2023. This surge in cases, particularly gallbladder cancers, signifies an unmet need for more effective therapies and diagnostic tools, further bolstering the gallbladder cancer market demand. The market is poised for further growth, primarily fueled by advancements in diagnostic technologies and the emergence of innovative therapeutics in the market.
The United States has been dominating the markets and is expected to lead the market in forecast period. This growth can be attributed to the increasing incidence of gallbladder cancer, the presence of key industry players, and the robust healthcare infrastructure in the region. Rising research and development continue to pave the way for novel interventions and diagnostic methods, contributing significantly to the rising gallbladder cancer market share, addressing critical healthcare gaps, and offering hope to affected individuals.
Gallbladder Cancer Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Gallbladder Cancer: Introduction
Gallbladder cancer originates from abnormal cell growth within the gallbladder, a small, pear-shaped organ located beneath the liver on the right side of the abdomen. Responsible for storing bile, a digestive fluid produced by the liver, the gallbladder plays a crucial role in the digestive process. Though uncommon, gallbladder cancer poses a significant challenge due to its tendency to remain asymptomatic in its early stages, often leading to late detection and a poor prognosis. The insidious nature of this cancer is exacerbated by its subtle symptoms or the absence thereof, allowing it to progress unnoticed.
Common signs such as upper right abdominal pain, bloating, unexplained weight loss, and jaundice, characterized by yellowing of the skin and eyes, might indicate the presence of gallbladder cancer, but these indicators often manifest in later stages, complicating timely diagnosis and treatment.
Gallbladder Cancer Market Analysis
The market for gallbladder cancer treatment is witnessing a transformative phase, driven by several key factors. The rise in demand and emphasis on targeted therapy treatments is further anticipated to bolster the gallbladder cancer market growth. For example, Gemcitabine, a combination therapy, has shown promising results, indicating an increased response rate compared to traditional treatments using 5-FU alone. The efficacy of gemcitabine in conjunction with cis-platinum and capecitabine highlights its potential as a viable treatment option.
Pembrolizumab has also shown positive results in tumours with high microsatellite instability/deficient mismatch repair, and entrectinib, a tyrosine kinase inhibitor, has potential use in NTRK gene fusion-positive tumours, providing a new pathway for gallbladder cancer treatment. These developments signify a shift towards more targeted and potentially more effective therapies, exhibiting hopeful market growth.
Gallbladder Cancer Market Segmentations
Gallbladder Cancer Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Stage I
- Stage II
- Stage III
- Stage IV
- Physical Examination
- Liver Function Test
- Blood Test
- CT Scan
- Ultrasound
- Percutaneous Transhepatic Cholangiography (PTC)
- Endoscopic Retrograde Cholangiopancreatography (ERC)
- Magnetic Resonance Imaging (MRI)
- Endoscopic ultrasound (EUS)
- Laparoscopy
- Biopsy
- Surgery
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Oral
- Injections
- Hospitals
- Gynaecology Clinics
- Academic and Research Centers
- United States
- EU-4 and the United Kingdom
- Japan
The market is experiencing significant growth driven by the rising prevalence of gallbladder cancer, especially among the geriatric population, which underscores the urgency for precision treatments. The statistics projected by the American Cancer Society for 2023 in the United States display concern by mentioning that a substantial number of new cases and related deaths are anticipated to occur in 2023. This surge in cases, particularly gallbladder cancers, signifies an unmet need for more effective therapies and diagnostic tools, further bolstering the gallbladder cancer market demand. The market is poised for further growth, primarily fueled by advancements in diagnostic technologies and the emergence of innovative therapeutics in the market.
The United States has been dominating the markets and is expected to lead the market in forecast period. This growth can be attributed to the increasing incidence of gallbladder cancer, the presence of key industry players, and the robust healthcare infrastructure in the region. Rising research and development continue to pave the way for novel interventions and diagnostic methods, contributing significantly to the rising gallbladder cancer market share, addressing critical healthcare gaps, and offering hope to affected individuals.
Gallbladder Cancer Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Cipla Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Sanofi
- OncoTherapy Science, Inc.
- Intuitive Surgical
- Sun Pharmaceutical Industries
- GLS Pharma Ltd.
- Symmetry Surgical Inc.
- CONMED Corporation
- Olympus Corporation
- Boston Scientific Corporation
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Gallbladder Cancer Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Gallbladder Cancer Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Gallbladder Cancer Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Gallbladder Cancer Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Gallbladder Cancer Epidemiology Forecast (2018-2034)
- 5.3.2 France Gallbladder Cancer Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Gallbladder Cancer Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Gallbladder Cancer Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Gallbladder Cancer Epidemiology Forecast (2018-2034)
- 5.4 Japan Gallbladder Cancer Epidemiology Forecast (2018-2034)
- 6 Gallbladder Cancer Market Overview – 7MM
- 6.1 Gallbladder Cancer Market Historical Value (2018-2024)
- 6.2 Gallbladder Cancer Market Forecast Value (2025-2034)
- 7 Gallbladder Cancer Market Landscape – 7MM
- 7.1 Gallbladder Cancer Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Gallbladder Cancer Product Landscape
- 7.2.1 Analysis by Type
- 7.2.2 Analysis by Treatments
- 7.2.3 Analysis by Route of Administration
- 8 Gallbladder Cancer Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Gallbladder Cancer Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Gallbladder Cancer Market Segmentation – 7MM
- 11.1 Gallbladder Cancer Market by Type
- 11.1.1 Market Overview
- 11.1.2 Stage I
- 11.1.3 Stage II
- 11.1.4 Stage III
- 11.1.5 Stage IV
- 11.2 Gallbladder Cancer Market by Diagnosis Type
- 11.2.1 Market Overview
- 11.2.2 Physical Examination
- 11.2.3 Liver Function Test
- 11.2.4 Blood Test
- 11.2.5 CT Scan
- 11.2.6 Ultrasound
- 11.2.7 Percutaneous Transhepatic Cholangiography (PTC)
- 11.2.8 Endoscopic Retrograde Cholangiopancreatography (ERC)
- 11.2.9 Magnetic Resonance Imaging (MRI)
- 11.2.10 Endoscopic ultrasound (EUS)
- 11.2.11 Laparoscopy
- 11.2.12 Biopsy
- 11.3 Gallbladder Cancer Market by Treatment
- 11.3.1 Market Overview
- 11.3.2 Surgery
- 11.3.3 Radiation Therapy
- 11.3.4 Chemotherapy
- 11.3.5 Immunotherapy
- 11.4 Gallbladder Cancer Market by Route of Administration
- 11.4.1 Market Overview
- 11.4.2 Oral
- 11.4.3 Injections
- 11.5 Gallbladder Cancer Market by End User
- 11.5.1 Market Overview
- 11.5.2 Hospitals
- 11.5.3 Gynaecology Clinics
- 11.5.4 Academic and Research Centers
- 11.6 Gallbladder Cancer Market by Region
- 11.6.1 Market Overview
- 11.6.2 United States
- 11.6.3 EU-4 and the United Kingdom
- 11.6.3.1 Germany
- 11.6.3.2 France
- 11.6.3.3 Italy
- 11.6.3.4 Spain
- 11.6.3.5 United Kingdom
- 11.6.4 Japan
- 12 United States Gallbladder Cancer Market
- 12.1 Gallbladder Cancer Market Historical Value (2018-2024)
- 12.2 Gallbladder Cancer Market Forecast Value (2025-2034)
- 12.3 Gallbladder Cancer Market by Disease Type
- 12.4 Gallbladder Cancer Market by Treatment Type
- 13 EU-4 and United Kingdom Gallbladder Cancer Market
- 13.1 Gallbladder Cancer Market Historical Value (2018-2024)
- 13.2 Gallbladder Cancer Market Forecast Value (2025-2034)
- 13.3 Germany Gallbladder Cancer Market Overview
- 13.3.1 Gallbladder Cancer Market by Disease Type
- 13.3.2 Gallbladder Cancer Market by Treatment Type
- 13.4 France Gallbladder Cancer Market Overview
- 13.4.1 Gallbladder Cancer Market by Disease Type
- 13.4.2 Gallbladder Cancer Market by Treatment Type
- 13.5 Italy Gallbladder Cancer Market Overview
- 13.5.1 Gallbladder Cancer Market by Disease Type
- 13.5.2 Gallbladder Cancer Market by Treatment Type
- 13.6 Spain Gallbladder Cancer Market Overview
- 13.6.1 Gallbladder Cancer Market by Disease Type
- 13.6.2 Gallbladder Cancer Market by Treatment Type
- 13.7 United Kingdom Gallbladder Cancer Market Overview
- 13.7.1 Gallbladder Cancer Market by Disease Type
- 13.7.2 Gallbladder Cancer Market by Treatment Type
- 14 Japan Gallbladder Cancer Market
- 14.1 Gallbladder Cancer Market Historical Value (2018-2024)
- 14.2 Gallbladder Cancer Market Forecast Value (2025-2034)
- 14.3 Gallbladder Cancer Market by Disease Type
- 14.4 Gallbladder Cancer Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Cipla Inc.
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 Bristol-Myers Squibb Company
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 Eli Lilly and Company
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 Pfizer Inc.
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 F. Hoffmann-La Roche Ltd
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 Sanofi
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 OncoTherapy Science, Inc.
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 Intuitive Surgical
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 Sun Pharmaceutical Industries
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 GLS pharma ltd.
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Symmetry Surgical Inc.
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 CONMED Corporation
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Olympus Corporation
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 Boston Scientific Corporation
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 21 Gallbladder Cancer Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
